The results showed that TP53 deletion (0%) had no significant influence on the TTF and OS of MCL patients (p = 0.10, HR = 1.45 and p = 0.18, HR = 1.46, respectively), while TP53 mutations (>50%) are highly predictive for short time to treat failure (TTF) and poor OS (both p < 0.0001; HR 2.47 and 3.00). This evidence concerns the gene TP53 and mantle cell lymphoma.